Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation

10 Apr 2023

Abstract excerpt

Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant primary brain tumor, and it is characterized by a high recurrence incidence and poor prognosis due to the presence of a highly heterogeneous mass of stem cells with self-renewal capacity and stemness maintenance ability. In recent years, the epigenetic landscape of GBM has been explored and many epigenetic alterations have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37108181
DOI: 10.3390/ijms24087017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent DifferentiationPMID 37108181Read ↗

BRD4 regulates self‐renewal ability and tumorigenicity of glioma‐initiating cells by enrichment in the Notch1 promoter regionSemantic proximity Read ↗

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsSemantic proximity Read ↗

BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cellsSemantic proximity Read ↗

BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells.Semantic proximity Read ↗

BRD4: New hope in the battle against glioblastomaSemantic proximity Read ↗

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expressionSemantic proximity Read ↗

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expressionSemantic proximity Read ↗

The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasionSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) MedulloblastomaSemantic proximity Read ↗

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseasesSemantic proximity Read ↗

Domain-selective targeting of BET proteins in cancer and immunological diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.